# A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Source: https://onco.cc/trials/nct07082686/  
OnCo record `nct07082686` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ICP-248 in mantle cell lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) is a phase 2 interventional study registered as NCT07082686 by Beijing InnoCare Pharma Tech Co., Ltd., with 75 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: ICP-248. Conditions listed: Relapsed or Refractory Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07082686
- Phase: 2
- Setting: A Single-arm, Multi-center, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07082686: https://clinicaltrials.gov/study/NCT07082686

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [ICP-248](https://onco.cc/drugs/icp-248/)

---
JSON: https://onco.cc/api/v1/entities/nct07082686.json